CD274 and breast cancer: This implies that PGRN is expected to become a new therapeutic target for breast cancer immunotherapy, and it may improve the efficacy of clinical immunotherapy in breast cancer via targeting PGRN combined with PD-L1 antibody or PD-1 antibody.